Navigation Links
Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
Date:6/29/2012

THE WOODLANDS, Texas, June 29, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today the publication of results from two initial trials of LX4211 in patients with type 2 diabetes in the online edition of the journal Clinical Pharmacology & Therapeutics. The paper, containing results from both trials, is entitled, "LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients with Type 2 Diabetes in a Randomized, Placebo-controlled Trial," and will also appear in an upcoming print edition of the journal. A link to the online article can be accessed at http://www.nature.com/clpt/journal/vaop/ncurrent/full/clpt201258a.html.

"This publication represents the first peer-reviewed description of SGLT1 inhibition stimulating GLP-1 and PYY release in man," said Dr. Brian Zambrowicz, Lexicon's executive vice president and chief scientific officer. "Since LX4211 also inhibits SGLT2, the rapid and significant glycemic control and metabolic benefits observed may be attributed to effective dual inhibition of these two targets."

In the 4-week Phase 2a study described in the paper, 36 patients received once-daily oral administration of placebo or 150 mg or 300 mg of LX4211 (randomized 1:1:1) in an in-patient setting. Patients receiving LX4211 exhibited rapid and significant improvements relative to placebo in multiple measures of glycemic control, including hemoglobin A1c (HbA1c), fasting plasma glucose, and oral glucose tolerance. In addition, serum triglycerides were significantly lower at the end of the four-week treatment period, and trends of meaningful reductions in body weight an
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
2. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
3. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
4. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
5. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
6. Lexicon to Provide First Quarter 2012 Financial Results
7. Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly
8. Hanger, Inc. Announces Second Quarter 2012 Earnings Release Conference Call
9. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
10. Marshall Edwards Announces Name Change to MEI Pharma ("MEIP")
11. Access Pharmaceuticals Announces Positive Data From MuGard Phase 4 Clinical Trial In Oral Mucositis At MASCC/ISOO 2012 Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Dec. 9, 2010 Customers using Elekta,s ... with seamless integration to Varian,s TrueBeam ™ ... to this linear accelerator is the most recent ... and the delivery systems of other cancer management ...
... Conn., Dec. 9, 2010 Boehringer Ingelheim Pharmaceuticals, Inc. ... the phase IIb/III LUX-Lung 1 trial show that afatinib ... 1.0 month for placebo) in progression-free survival (PFS) in ... to have an epidermal growth factor receptor (EGFR) mutation.(1) ...
Cached Medicine Technology:Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 2Cancer Treatment Centers' Oncology Information System Options Expand with New MOSAIQ Connectivity 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 2New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 3New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 4New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations 5
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... Two recent papers by a University of Colorado ... scientists develop treatments or vaccines for Dengue fever, ... other disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, ... the School of Medicine and an early career ... colleagues recently published articles in the scholarly journals ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... 17, 2014 By discovering a new mechanism that ... stroke, researchers at UC Irvine and the Salk Institute ... limit or prevent stroke-induced brain damage. , A complex ... of death and primary reason for disability in the ... stroke and lets blood-borne material into the brain, causing ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... recall as number of people sickened in outbreak rises to ... Jan. 14 (HealthDay News) -- A nationwide recall of peanut ... even as the number of people sickened by salmonella-contaminated peanut ... of America, based in Lynchburg, Va., issued the recall of ...
... effort by national SEIU officials to oust reformers, ... United Healthcare Workers (UHW) President Sal Rosselli and ... afternoon, according to UHW election committee chair Debby ... by national SEIU President Andy Stern to oust ...
... had fewer problems and a much higher quality of life ... three weeks after being discharged from hospital, according to research ... Nursing . , During the two-year study, researchers from Umea ... pedestrians who had attended the same emergency department after an ...
... Obesity continues to increase for women in the United ... ages of 35-44, there are approximately 3.3 million white ... who are obese. A new study published in the ... is an increased risk for midlife obesity among Mexican-American ...
... study from Indiana University suggests that even meager levels ... with serious mental illnesses (SMI) such as bipolar disorder, ... in the November issue of the " International Journal ... people with SMI demonstrate low levels of physical activity ...
... Jan. 14 Genworth Financial,s Long Term Care (LTC) ... the National LTC Network to sell Genworth,s long term ... National LTC Network will offer Genworth,s long term care ... will help expand Genworth,s distribution of its long term ...
Cached Medicine News:Health News:More Peanut Butter Recalled in Salmonella Outbreak 2Health News:More Peanut Butter Recalled in Salmonella Outbreak 3Health News:United Healthcare Workers Re-Elect All Statewide Officers 2Health News:Telephone support after traffic accidents reduces problems and improves quality of life 2Health News:Telephone support after traffic accidents reduces problems and improves quality of life 3Health News:Economic status affects obesity rates in Mexican-American and white women 2Health News:Physical activity, mood and serious mental illness 2Health News:Genworth Forges Strategic Relationship with National LTC Network 2
CCR Medical conventional laryngoscopes....
... Original LMA™ Airway., ,Launched in 1988, ... use is now standard practice in general ... worldwide the LMA Classic™ is a safe ... ,The LMA Classic™ can be used ...
... , ,Developed for cardiopulmonary resuscitation and ... LMA Fastrach™ has been designed to facilitate ... neck. The LMA Fastrach™ allows continuous ventilation ... emergency teams worldwide including NASA for its ...
... the production of airway management ... integrated solution to all your ... Portex Soft Seal Laryngeal Mask ... this wide portfolio of products ...
Medicine Products: